Page 18 - Nasdaq Cytk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq cytk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cytk Today - Breaking & Trending Today

Quent Capital LLC Buys New Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Quent Capital LLC bought a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,800 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. A number of other hedge funds and other […] ....

Sakhalinskaya Oblast , United States , Fady Ibraham Malik , Roberti Blum , Quent Capital , Cantor Fitzgerald , Securities Exchange Commission , Needham Company , Exchange Commission , Cytokinetics Inc , Financial Services Group Inc , Cytokinetics Incorporated , Metlife Investment Management , Get Rating , Financial Advisors , Life Investment Management , Services Group , Maryland State Retirement , Pension System , State Retirement , Ibraham Malik , Cytokinetics Daily , Nasdaq Cytk , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

36,042 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Guggenheim Capital LLC

Guggenheim Capital LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 36,042 shares of the biopharmaceutical company’s stock, valued at approximately $1,747,000. Several other large investors […] ....

United States , Sakhalinskaya Oblast , Robert Wong , Roberti Blum , Cytokinetics Incorporated , Securities Exchange Commission , Cytokinetics Inc , Principal Financial Group Inc , Oregon Public Employees Retirement Fund , Guggenheim Capital , Get Rating , Financial Group , Pension Plan Investment Board , Public Employees Retirement Fund , Louisiana State Employees Retirement System , Cytokinetics Daily , Nasdaq Cytk , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Cytokinetics Presents Positive Results From Cohort 4 of

Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive. ....

United States , Sara Saberi , Fadyi Malik , Diane Weiser , Ahmad Masri , York Heart Association , Omni Riverfront Hotel , Research Evaluation Of Sustained Treatment , Research Development , American College Of Cardiology , Company To Host Investor Event , Cytokinetics Incorporated Nasdaq , Exchange Commission , Us Food Drug Administration , University Of Michigan Health Frankel Cardiovascular Center , Corporate Communications , National Medical Products Administration , Aficamten Resulted , Significant Improvements , Heart Failure Symptoms , Cardiac Biomarkers , Supporting Advancement , Long Term Treatment , Sustained Treatment , Host Investor Event , Conference Call ,

Cytokinetics Receives Complete Response Letter From FDA for

Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to. ....

United States , Ruoxiang Jiang , Susana Weston , Shannonm Dunlay , Margaretm Redfield , Omecamtiv Mecarbil , Diane Weiser , Roberti Blum , American Heart Association , Heart Failure Association , Company Expects To Request Meeting , Drug Administration , Exchange Commission , Cytokinetics Incorporated Nasdaq , Corporate Communications , European Society Of Cardiology , Circulation Research , Complete Response Letter States , Establish Substantial Evidence , Effectiveness Sufficient , Request Meeting , Discuss Potential Next Steps , Host Conference Call , Complete Response Letter , New Drug Application , Global Approach ,

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 10,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $42.43, for a total transaction of $424,300.00. Following the completion of the transaction, the chief executive officer now directly owns 406,412 shares […] ....

United States , Roberti Blum , Cytokinetics Incorporated , Everence Capital Management Inc , Jpmorgan Chase Co , Russell Investments Group Ltd , Principal Financial Group Inc , Get Rating , Investments Group , Financial Group , State Retirement System , State Employees Retirement System , Everence Capital Management , Capital Management , Cytokinetics Daily , Nasdaq Cytk , Insider Trading , Nsider Trades ,